No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands

Timmermans, Maite; Sonke, Gabe S.; Vijver, Koen K. Van de; Aa, M.A. van der; Kruitwagen, Roy F.P.M.

doi:10.1016/j.ejca.2017.10.030

Cited by 109 publications

(88 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surgical resection combined with chemotherapy is the firstline treatment for OvCa, which has been demonstrated to improve the prognosis of patients. However, the overall fiveyear survival rate remains lower (approximately 30%) [3,4] because more than 70% of patients [5] may experience recurrence, ultimately resulting in the treatment failure. erefore, early identification of patients with a high recurrence risk is necessary in order to schedule personalized therapies and improve prognostic outcomes.…”

Section: Introductionmentioning

confidence: 99%

Recurrence‐Associated Multi‐RNA Signature to Predict Disease‐Free Survival for Ovarian Cancer Patients

Chen

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Ovarian cancer (OvCa) is an intractable gynecological malignancy due to the high recurrence rate. Several molecular biomarkers have been previously screened for early identifying patients with a high recurrence risk and poor prognosis. However, all the known studies focused on a single type of RNAs, not integrating various types. This study was to construct a new multi-RNA-based model to predict the recurrence and prognosis for OvCa patients by using the messenger RNA (mRNA, including long noncoding RNA (lncRNA)) and microRNA (miRNA) sequencing data of The Cancer Genome Atlas database. After univariate Cox regression and least absolute shrinkage and selection operator analyses, a multi-RNA-based signature (2 miRNAs: hsa-miR-508, hsa-miR-506; 1 lncRNA: TM4SF1-AS1; 11 mRNAs: MAGI3, SLAMF7, GLI2, PDK1, ARID3A, PLEKHG4B, TNFAIP8L3, C1QTNF3, NDUFAF1, CH25H, TMEM129) was generated and used to establish a risk score model. The high- and low-risk patients classified by the median risk score exhibited significantly different recurrence risks (89% versus 61%, p<0.001) and survival time (the area under the receiver operating characteristic curve (AUC) = 0.901 for 5-year disease-free survival (DFS)). This risk model was independent of other clinical features and superior to pathologic staging for DFS prediction (AUC, 0.906 versus 0.524; C-index, 0.633 versus 0.510). Furthermore, some new interaction axes were revealed to explain the possible functions of these RNAs (competing endogenous RNA: TM4SF1-AS1-miR-186-STEAP2, LINC00536-miR-508-STEAP2, LINC00475-miR-506-TMEM129; coexpression: LINC00598-PLEKHG4B). In conclusion, this multi-RNA-based risk model may be clinically useful to stratify OvCa patients with different recurrence risks and survival outcomes and included RNAs may be potential therapeutic targets.

show abstract

Section: Introductionmentioning

confidence: 99%

Recurrence‐Associated Multi‐RNA Signature to Predict Disease‐Free Survival for Ovarian Cancer Patients

Chen

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…1 The 10-year survival of women with advanced-stage ovarian cancer is 10% to 15% and has not improve in the past 20 years. 2,3 Despite treatment with maximal cytoreductive surgery (CRS) and platinum-based chemotherapy, approximately 70% of patients with advanced-stage disease relapse within 18 months. Given this high number of recurrences, new approaches are needed to improve outcomes for these patients.…”

Section: Introductionmentioning

confidence: 99%

Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial

Koole¹,

Lieshout²,

Driel³

et al. 2019

Obstetrical &Amp; Gynecological Survey

View full text Add to dashboard Cite

PURPOSE In the randomized open-label phase III OVHIPEC trial, the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improved recurrence-free and overall survival in patients with stage III ovarian cancer. We studied the cost effectiveness of the addition of HIPEC to interval CRS in patients with ovarian cancer. PATIENTS AND METHODS We constructed a Markov health-state transition model to measure costs and clinical outcomes. Transition probabilities were derived from the OVHIPEC trial by fitting survival distributions. Incremental cost-effectiveness ratio (ICER), expressed as euros per quality-adjusted life-year (QALY), was calculated from a Dutch societal perspective, with a time horizon of 10 years. Univariable and probabilistic sensitivity analyses were conducted to evaluate the decision uncertainty. RESULTS Total health care costs were V70,046 (95% credibility interval [CrI], V64,016 to V76,661) for interval CRS compared with V85,791 (95% CrI, V78,766 to V93,935) for interval CRS plus HIPEC. The mean QALY in the interval CRS group was 2.12 (95% CrI, 1.66 to 2.64 QALYs) and 2.68 (95% CrI, 2.11 to 3.28 QALYs) in the interval CRS plus HIPEC group. The ICER amounted to V28,299/QALY. In univariable sensitivity analysis, the utility of recurrence-free survival and the number of days in the hospital affected the calculated ICER most. CONCLUSION On the basis of the trial data, treatment with interval CRS and HIPEC in patients with stage III ovarian cancer was accompanied by a substantial gain in QALYs. The ICER is below the willingness-to-pay threshold in the Netherlands, indicating interval CRS and HIPEC is cost effective for this patient population. These results lend additional support for reimbursing the costs of treating these patients with interval CRS and HIPEC in countries with comparable health care systems.

show abstract

“…In the HIPEC [ 9 6 _ T D $ D I F F ] and DD chemotherapy group (n = 64), the patients' mean age was 59.9 (SD = 11.36) years; the subjects' age for the IP cohort (n = 81) and DD group (n = 100) was 57.8 (SD = 12.02) years and 62.9 (SD = 10.46) years, respectively (P = 0.301). The mean body mass index (BMI) was 29.2 kg/m 2 (SD = 6.00) for the DD chemo and HIPEC group, 27.9 kg/m 2 (SD = 5.71) for the IP group and 28.1 kg/m 2 When considering total lines of therapy, the HIPEC [ 1 0 3 _ T D $ D I F F ] and DD chemo patients underwent a mean 2.36 (SD = 1.67) chemotherapy regimens, the IP cohort was treated with a mean of 2.41 (SD = 1.74) and the DD group was administered 3.00 (SD = 1.60) regimens (P = 0.019); the DD group received significantly more chemotherapy regimens than both the IP and HIPEC groups.…”

Section: Patient Demographicsmentioning

confidence: 99%

“…Ovarian cancer is the most aggressive gynecologic malignancy and associated with very high mortality rates. Despite advances in surgery and chemotherapeutic agents, 5-year survival rates for this disease have primarily remained unchanged [2][3][4], warranting further evaluation of the type and manner with which chemotherapy regimens are administered.…”

Section: Commentsmentioning

confidence: 99%

“…Ovarian cancer is the most aggressive gynecologic malignancy, accounting for nearly 14,335 deaths in the United States in 2018 [1]. The neoplasm frequently presents itself with advanced stage clinical features and has an attendant five-year survival rate of nearly 35 % [2]. Despite the inclusion of surgery and standard chemotherapy, most patients will ultimately succumb to their disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma

Rettenmaier¹,

Micha

Bohart³

et al. 2020

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands

Cited by 109 publications

References 45 publications

Recurrence‐Associated Multi‐RNA Signature to Predict Disease‐Free Survival for Ovarian Cancer Patients

Recurrence‐Associated Multi‐RNA Signature to Predict Disease‐Free Survival for Ovarian Cancer Patients

Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial

A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma

Contact Info

Product

Resources

About